beyondMD launches provider-led peptide telehealth platform

beyondMD has launched BMD Peptides, a virtual care service that lets patients be evaluated by licensed providers for peptide therapy and receive prescriptions only when clinically appropriate. The company says the platform is built around provider review, compounding-pharmacy fulfillment and patient education, not retail supplement sales.

Why it matters: - BMD Peptides enters a crowded telehealth market with a provider-led model centered on prescription-only care. - The platform could expand access to peptide therapy for patients in states where beyondMD’s licensed network can operate. - The service emphasizes clinical evaluation and follow-up, which may appeal to patients looking for more oversight than a direct-to-consumer storefront.

What happened: - beyondMD launched BMD Peptides, a virtual care platform for peptide therapy. - Patients can be evaluated by a licensed healthcare provider before any prescription is written. - Prescribed medications are dispensed by a licensed U.S. 503A compounding pharmacy. - beyondMD says its provider network is licensed in all 50 states. - The platform is operated by beyondMD, a telehealth company based in Houston.

The details: - BMD Peptides is prescription-only. - The site does not offer dietary supplements, vitamins or over-the-counter products. - No medication is shipped without a prescription from a licensed provider after an individual clinical evaluation. - Patients who choose to move forward complete an online intake covering health history, current medications and treatment goals. - beyondMD’s clinical team includes physicians, a doctor of osteopathic medicine and nurse practitioners. - Providers review the intake to decide whether treatment is appropriate for that patient. - Patients who receive a prescription also get usage guidance and provider follow-up. - Compounded medications are prepared to meet an individual prescription and are not FDA-approved products. - FDA does not review compounded formulations for safety or effectiveness before dispensing. - Many peptide therapies described on the site are not FDA-approved for the uses discussed and may be prescribed off-label at a provider’s discretion. - The platform includes a reference library on mechanisms, evidence and regulatory status for peptides providers may prescribe. - The educational material is meant to prepare patients for a provider conversation, not replace one. - Patients can contact beyondMD’s care team by phone before or after an evaluation. - Availability of each program varies by state and by clinical suitability. - Individual results vary.

Between the lines: - beyondMD is positioning BMD Peptides as a medical service first, which helps distinguish it from supplement-driven wellness brands. - The company is leaning on clinical review and compounding-pharmacy fulfillment to frame the platform as more regulated than typical online wellness offerings. - The inclusion of educational content suggests beyondMD wants to guide patient expectations around both evidence and regulatory limits. - Founder Deborah Shurlow said the company wanted to build a clinical service, not a storefront, and that patients should have the chance to ask questions and understand options before treatment begins.

What's next: - Patients who meet clinical criteria can move from intake to provider review and, if appropriate, prescription fulfillment. - Program availability will continue to depend on state rules and individual clinical decisions. - beyondMD is expected to keep steering patients to its educational resources and care team before and after evaluation.

The bottom line: - BMD Peptides is beyondMD’s bet that patients want peptide therapy through a licensed-provider workflow rather than an e-commerce model. - More information is available at the company's announcement.